ClinicalTrials.gg
RecruitingNCT07400003Updated Feb 10, 2026

Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine

A Phase 1/2 interventional study of Low-dose experimental vaccine and High-dose experimental vaccine in Herpes Zoster and mRNA Vaccine, sponsored by Sinovac Biotech Co., Ltd. Recruiting at 1 site in China. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Sinovac Biotech Co., Ltd · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
519
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Herpes Zoster with a site in China — 26 open to participants now, 31 under way, 3 of them phase 3. Herpes Zoster · China.

Planned enrollment
23rd of 45
519 · median 519
Started
2026
with 5 others
Phase 1/2
6 of 51
4 open now
Primary completion
2026-05
later than 10 of 30 live
Registered
47th of 51
by date

Among the 51 studies in Herpes Zoster with a site in China, this one is the 23rd largest by planned enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2026, is one of 6 in phase 1/2, reaches primary completion later than 10 of the 30 other live ones, and was the 47th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

26 of the 51 studies in Herpes Zoster with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Herpes Zoster with a site in China, or all of them as a file.
02

Study summary

This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40 years and older. The goal of Part B is to select the optimal dosage and schedule in healthy populations aged 50 years and older to support next further study.

Read the detailed description

This is a randomized, double-blind, controlled study. Part A employed sequential enrollment by age and dosage. All participants received two doses of the study vaccine. Safety observation conducted throughout the study. Humoral and celluar immunity were evaluated.

In Part B, participants randomly received either different dosage study vaccine or active controlled vaccine, with different immunization schedule. Safety observation conducted throughout the study. Humoral and celluar immunity were evaluated. Immune persistence was also evaluated at multiple timepoints after vaccination.

03

Conditions studied

  • Herpes Zoster
  • mRNA Vaccine

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase I: Age ≥ 40 years; Phase II: Age ≥ 50 years;
  • Participants are able to understand and voluntarily sign the form;
  • Able to provide legal identification;
  • Participants of and their sexual partners agree to voluntarily adopt effective measures from the signing of the informed consent form until 6 months after the last dose of the vaccine, with no plans for sperm or egg donation;
  • Agree to comply with the visit schedule, sample collection, vaccination, and other trial procedures throughout the study period, and remain accessible at all times during the trial.

Exclusion criteria

Exclusion Criteria:

  • History of chickenpox or herpes zoster in adulthood;
  • History of chickenpox or herpes zoster vaccination (including administration of registered products or participation in clinical trials of chickenpox or herpes zoster vaccines);
  • Close contact with patients infected with chickenpox or herpes zoster within the past 30 days;
  • abnormalities in protocol-specified clinical laboratory tests prior to vaccination (applicable to Phase I clinical trials only):

A. Hematological parameters: White blood cell count (WBC), (Hb), count (Plt); B. Blood biochemical parameters: (ALT), aspartate aminotransferase (AST), total (TBIL), fasting blood glucose (Glu), creatinine (CR); C. Urinalysis parameter: Urine protein (PRO); D. Coagulation parameters: (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib), international normalized ratio (INR); E. 12-lead (ECG).

  • Poorly controlled chronic diseases or significant medical history, including but not limited to cardiovascular diseases (e.g., poorly controlled hypertension defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg for participants aged 40-59 years prior to enrollment, or systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg for participants aged ≥60 years), metabolic disorders (e.g., poorly controlled diabetes), hematological diseases, hepatic or renal diseases, digestive system diseases, respiratory system diseases, history of major organ transplantation, or within the past five years;
  • History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or any condition that increases the risk of myocarditis or pericarditis;
  • diseases, immunodeficiency diseases, or family history thereof (including but not limited to psoriasis, systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, acute disseminated encephalomyelitis, facial paralysis, reactions, polymyalgia rheumatica, rheumatoid arthritis, Guillain-Barré syndrome, asplenia, functional asplenia, infection);
  • Coagulation disorders (e.g., coagulation factor deficiencies, platelet abnormalities, or other coagulopathies);
  • Current or previous severe neurological disorders (epilepsy, convulsions, or seizures) or psychiatric illnesses, or family history of psychiatric disorders;
  • Acute illnesses or acute exacerbations of chronic diseases within the past 7 days, or known or suspected active infections;
  • therapy or other immunomodulatory treatments (prednisone ≥20 mg/day or equivalent for >14 days), cytotoxic therapy within the past 6 months, or planned use during the trial;
  • Administration of immunoglobulins or other blood products within the past 3 months (use of immunoglobulin within the past 1 month), or planned use during the trial;
  • Participation in other clinical studies within the past 30 days or planned participation during this trial;
  • Vaccination with or nucleic acid vaccines within the past 28 days, or vaccination with subunit, inactivated, or other types of vaccines within the past 14 days;
  • Known allergy to vaccines or vaccine components, such as urticaria, dyspnea, or angioedema following vaccination;
  • Pregnancy, lactation, or positive urine pregnancy test in female participants;
  • Fever (axillary temperature ≥37.3°C) within 3 days prior to vaccination or use of antipyretics, analgesics, or antihistamines (e.g., acetaminophen, ibuprofen, loratadine, cetirizine, etc.) as reported during inquiry;
  • Physical examination deemed unsatisfactory on the day of planned vaccination;
  • Skin lesions, inflammation, ulcers, rashes, scars, or other conditions at the target injection site that may interfere with administration or local reaction assessment;
  • Any other factors deemed by the investigator to render the participant unsuitable for participation in the clinical trial.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
519 participants (estimated)

Study arms

  • Experimental
    Low-dose group

    Participants will receive two doses of lyophilized herpes zoster virus mRNA vaccine (low dosage), with 30 days or 60 days apart

    Biological: Low-dose experimental vaccine

  • Experimental
    High-dose group

    Participants will receive two doses of lyophilized herpes zoster virus mRNA vaccine (high dosage), with 30 days or 60 days apart

    Biological: High-dose experimental vaccine

  • Active comparator
    Comparator A

    Participants will receive a single dose of saline on day 0 and a single dose of herpes zoster vaccine, live on day 60

    Biological: Active-controlled vaccine A

  • Active comparator
    Comparator B

    Participants will receive two doses of recombinant zoster vaccine (CHO cell), with 60 days apart

    Biological: Active-controlled vaccine B

  • Placebo comparator
    Comparator C

    Participants will receive two doses of saline, with 60 days apart

    Other: Placebo group

Interventions

  • BiologicalLow-dose experimental vaccine

    Lyophilized herpes zoster virus mRNA vaccine

  • BiologicalHigh-dose experimental vaccine

    Lyophilized herpes zoster virus mRNA vaccine

  • BiologicalActive-controlled vaccine A

    herpes zoster attenuated live vaccine, lyophilized

  • BiologicalActive-controlled vaccine B

    Shingrix®

  • OtherPlacebo group

    Saline

06

What researchers measure

Primary outcomes

  1. The incidence of adverse reactions within 30 days

    The incidence of adverse reactions within 0\~30 days after each dose vaccination.

    Time frame: 0~30 days after each dose vaccination

  2. Seroconversion rate of gE antibody

    The seroconversion rate of gE antibody on Day 30 after two doses vaccination.

    Time frame: Day 30 after two doses

  3. Geometric mean concentration (GMC) of gE antibody

    The GMC of gE antibody on Day 30 after two doses vaccination.

    Time frame: Day 30 after two doses

Secondary outcomes

  1. Adverse reactions within 0~14 days

    The incidence of adverse reactions within 0\~14 days after each dose vaccination.

    Time frame: 0~14 days after each dose vaccination

  2. Incidence of serious adverse events (SAEs)

    The incidence of SAEs from the first dose to 12 months after the second dose.

    Time frame: From the first dose to 12 months after the second dose

  3. Incidence of adverse events of special interest(AESI)

    The incidence of AESI from the first dose to 12 months after the second dose.

    Time frame: From the first dose to 12 months after the second dose

  4. GMC of gE antibody

    The GMC of gE antibody on Day 30 or Day 60 after the first dose, and on Day 14、Day 180 and Day 360 after the second dose

    Time frame: On Day 30 or Day 60 after the first dose, and on Day 14、Day 180 and Day 360 after the second dose

  5. Geometric mean fold rise (GMFR) of gE antibody

    The GMFR of gE antibody on Day 30 or Day 60 after the first dose, and on Day 14 and Day 30 after the second dose

    Time frame: On Day 30 or Day 60 after the first dose, and on Day 14 and Day 30 after the second dose

  6. Seroconversion rate of varicella-zoster virus (VZV) antibody

    The seroconversion rate of VZV antibody on Day 30 or Day 60 after the first dose, and on Day 14、Day 30、Day 180 and Day 360 after the second dose.

    Time frame: On Day 30 or Day 60 after the first dose, and on Day 14、Day 30、Day 180 and Day 360 after the second dose

  7. GMT of VZV antibody

    The GMT of VZV antibody on Day 30 or Day 60 after the first dose, and on Day 14、Day 30、Day 180 and Day 360 after the second dose

    Time frame: On Day 30 or Day 60 after the first dose, and on Day 14、Day 30、Day 180 and Day 360 after the second dose

  8. GMFR of VZV antibody

    The GMFR of VZV antibody on Day 30 or Day 60 after the first dose, and on Day 14 and Day 30 after the second dose

    Time frame: On Day 30 or Day 60 after the first dose, and on Day 14 and Day 30 after the second dose

  9. Frequency of CD4/CD8+ T cells secreting gE-specific cytokines

    The frequency of CD4/CD8+ T cells secreting gE-specific cytokines (IFN-γ, IL-2, TNF-α, CD40L) on Day 30 or Day 60 after the first dose, and on Day 14、Day 30、Day 180 and Day 360 after the second dose.

    Time frame: On Day 30 or Day 60 after the first dose, and on Day 14、Day 30、Day 180 and Day 360 after the second dose

  10. Cellular immune response rate

    The cellular immune response rate on Day 30 or Day 60 after the first dose, and on Day 14 and Day 30 after the second dose.

    Time frame: On Day 30 or Day 60 after the first dose, and on Day 14 and Day 30 after the second dose

07

Study locations

1 of 1 sites recruiting
  • Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention
    Xinjiang, 831100, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for May 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 10, 2026
StartActual
Jan 6, 2026
Primary completionEst.
May 31, 2026
CompletionEst.
Apr 30, 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07400003
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Jan 6, 2026
Primary completion
May 31, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Na Xie
Contact
xn@xjcdc.com
86+1999015105
Jiao Xue
Contact
64282811@qq.com
86+13899089997
Na Xie
principal investigator · Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion